HIV Infections Clinical Trial
Official title:
Secondary Distribution of HIV Self-tests Through Antenatal and HIV Testing Services: a Pragmatic Cluster-randomized Trial (STAR-ANC)
A three arm cluster randomized trial randomizing government primary health clinics to a)
standard of care (SOC) with clinic invitation only; b) standard of care (SOC) and one
self-test kit to give to sexual partner (s); c) standard of care (SOC) and self-test kit and
monetary incentive given to partner conditional on clinic attendance and completion of
pre-set procedures to determine secondary accuracy.
Trial to be conducted in four districts (Blantyre, Zomba, Machinga and Chikwawa) in Malawi in
collaboration with the Ministry of Health.
Two primary outcomes:
1. proportion of male partners of antenatal care clinic attendees reported by the woman to
have tested for human immunodeficiency virus (HIV) within 28 days of enrolling the woman
2. Number of new HIV positives identified by providing trial services to newly tested HIV
positive clients in routine HIV testing service within 28 days of enrolling the index
client.
Data analysed as intention to treat with all eligible antenatal care (ANC) attendees and
index clients at each health facility as the denominator, with unpaired t-test used to
compare each intervention arm to the standard of care (SOC).
Type of study: This proposal is for a 3-arm pragmatic cluster randomised trial (CRT) using
primary care clinics as the unit of randomisation. The three arms are: 1) Standard of care
(SOC) with written invitation to the partner, and two intervention arms of 2) standard of
care (SOC) + HIV self-test kits delivered by the partner; and 3) arm 2 plus a monetary
incentive for partners who participate in a linked-accuracy study.
Problem: Malawi's Ministry of Health (MoH) uses a highly decentralized approach for delivery
of HIV services that delivers over 3 million HIV tests each year, and has taken the country
close to The Joint United Nations Programme on HIV and AIDS (UNAIDS) 90-90-90 targets.
However, a testing gap remains among populations with barriers to accessing facility-based
HIV testing services (HTS), including men. The investigators recently showed
partner-delivered (secondary distribution) of HIV self-testing (HIVST) kits, via women
attending antenatal care (ANC) in urban Blantyre, to be effective at increasing the uptake of
HIV testing and subsequent HIV care and prevention services among male partners. However,
unanswered questions that remain to be addressed include:
- the accuracy of HIV self-testing (HIVST) when kits are provided by secondary
distribution
- how effective secondary distribution is when fully devolved to Ministry of Health (MoH)
providers ("pragmatic")
- whether the high safety profile and acceptability of secondary distribution of HIV
self-test kits from antenatal care (ANC) clinics can be generalised to other clinic
services.
Role of Ministry of Health (MoH), implementers and researchers: HIV self-test kits will be
delivered by the HIV Department of Ministry of Health (MoH), Malawi, in partnership with
Population Services International (PSI)-Malawi. Ministry of Health (MoH) aims to routinely
scale-up secondary distribution from antenatal care (ANC) clinics in high HIV prevalence
districts, and HIV testing services (HTS) nationally if results are satisfactory.
Research Question: Can secondary distribution of HIV self-tests through antenatal care and
HIV testing services improve coverage of HIV testing in sexual partners of pregnant women and
newly-diagnosed people living with HIV (PLHIV), while maintaining low costs and acceptable
linkage, safety and accuracy?
Objectives: The broad objective is to determine the feasibility, benefits, costs, safety and
accuracy of secondary distribution of HIV self-test kits from routine antenatal and HIV
testing services (HTS) clinics in Malawi. The specific aims are to conduct a pragmatic
cluster randomized trial to:
1. Assess the feasibility of programmatic implementation of secondary distribution of HIV
self-test kits from routine Ministry of Health (MoH) clinics.
2. Establish the effectiveness of secondary distribution of HIV self-test kits on:
1. HIV testing among male partners of antenatal care (ANC) attendees
2. Initiation of antiretroviral therapy (ART) and uptake of voluntary medical male
circumcision (VMMC) among male partners of antenatal care attendees
3. Disclosure and couple testing among male partners of antenatal care attendees
4. Identification of HIV-positive contacts among partners of newly diagnosed
HIV-positive index clients through routine HIV testing services (HTS).
3. Investigate the impact of secondary distribution of HIV self-test kits on the frequency
of social harms affecting distributors of HIV self-test kits
4. Estimate the costs and cost-effectiveness of adding secondary distribution of HIV
self-test kits to the antenatal care and HIV testing service.
5. Estimate the sensitivity and specificity of OraQuick HIV self-test kits under secondary
distribution.
Methodology Participants and intervention Pregnant women registering for antenatal care in 27
primary health clinics and newly diagnosed HIV+ clients from the same 27 clinics in Blantyre,
Chikwawa, Machinga and Zomba Districts. Restricted randomisation will be used to allocate
clinics to the 3 arms (1:1:1). Ministry of Health (MoH) Clinic staff in the HIV self-testing
arms will be trained in use of oral HIVST kits (OraQuick). HIV self-test kit supply will use
Ministry of Health (MoH) supply chains. Information and educational materials will include a
tablet with a video clip demonstrating correct use of kits. Data capture tools and training
materials will be developed with Ministry of Health (MoH).
A full-time research assistant will support research-data capture at each clinic. For the
accuracy sub-study this will include a brief questionnaire, repeat HIV testing (2
finger-prick HIV rapid diagnostic tests plus repeat OraQuick) and dried blood spots (DBS) for
antiretroviral therapy (ART) drug and HIV viral load testing.
Primary and secondary outcomes:
The two primary outcomes are comparison between standard of care (SOC) and HIV self-testing
arms of:
1. % of women reporting that their partner has tested for HIV within 28 days of ANC
appointment.
2. Number of previously undiagnosed people living with HIV (PLHIV) identified among
partners of HIV-positive index patients by Day 28
The six secondary outcomes are:
1. % of partners of antenatal care attendees who start antiretroviral therapy (ART),
undergo voluntary medical male circumcision (VMMC), or attend discordant couples clinic
within 28 days of enrolling the woman
2. % of partners of antenatal care attendees who attend the clinic for any HIV services
within 28 days of enrolling the woman
3. % HIV+ index clients who self-report at least one partner tested for HIV as a result of
their diagnosis, measured at Day 28
4. Number of partners of HIV testing services (HTS) index clients who start antiretroviral
therapy (ART), or undergo voluntary medical male circumcision (VMMC), or attend
discordant couples clinic within 28 days of index diagnosis
5. Number of partners of HIV+ Index clients who attend the clinic for any HIV services
within 28 days of index diagnosis
6. Risk of adverse events (e.g. partnership breakdown, intimate partner violence, etc.)
related to self-testing reported by antenatal care / HIV-positive index clients,
measured at Day 28
Sample size:
9 clinics per arm each recruiting 350 antenatal care clients and 135 newly diagnosed people
living with HIV (PLHIV) will provide 90% power to detect a 12% absolute difference in the
primary outcome, assuming 20% of standard of care (SOC) partners, and a coefficient of
variation (k) of 0.25. Cluster-level summaries with a t-test applied to the mean of clinic
proportions will be compared to the standard of care (SOC) for the primary outcome.
Ethical considerations: The investigators request a waiver of informed consent for HIV
self-testing, as this is now international best practice, and delivery will be by Ministry of
Health (MoH) routine systems. Written informed consent (witnessed thumb-print if illiterate)
will be taken from all participants in the accuracy sub-study.
Dissemination: The results will be used to inform Ministry of Health (MoH) on HIV
self-testing scale-up plans, and will also be disseminated through College of Medicine in
Blantyre including College of Medicine Research Ethics Committee (COMREC), and through
conference presentations and publication in peer-reviewed journal.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |